Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Valion Bio (TIVC) Change in Working Capital (2025)

Valion Bio has reported Change in Working Capital over the past 1 years, most recently at $2000.0 for Q1 2025.

For Q1 2025, Change in Working Capital changed N/A year-over-year to $2000.0; the TTM value through Jun 2025 reached $2000.0, changed N/A, while the annual FY2024 figure was -$34000.0, N/A changed from the prior year.
Change in Working Capital for Q1 2025 was $2000.0 at Valion Bio.
Over five years, Change in Working Capital peaked at $2000.0 in Q1 2025 and troughed at $2000.0 in Q1 2025.